Contraception
Volume 80, Issue 3 , Pages 245-253 , September 2009

Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen

  • David F. Archer

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 757 446 7444.
    • ,
  • George Kovalevsky

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    • ,
  • Susan A. Ballagh

      Affiliations

    • CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    • ,
  • Gary S. Grubb

      Affiliations

    • Women's Health, Clinical Research/Development, Wyeth Research, Collegeville, PA 19426, USA

Received 6 October 2008 ,Revised 13 March 2009 ,Accepted 15 March 2009.

References 

  1. Kuntz AM. Menstruation: choosing whether and when. Contraception. 2000;62:277–284
  2. Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception. 2006;74:359–366
  3. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142–1149
  4. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003;101:653–661
  5. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results. Contraception. 2006;74:439–445
  6. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril. 1999;72:115–120
  7. Birtch RL, Olatunbosun OA, Pierson RA. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use. Contraception. 2006;73:235–243
  8. Schlaff WD, Lynch AM, Hughes HD, Cedars MI, Smith DL. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am J Obstet Gynecol. 2004;190:943–951
  9. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception. 1993;47:583–590
  10. Belsey EM. Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Methods of contraception. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Adv Contracept. 1991;7:257–270
  11. Craig LB, Miller L, Criniti A. Rapid resumption of ovulation and menstruation following continuous use of the combination oral contraceptive. Fertil Steril. 2005;83(suppl 2):S16;[Abstract].
  12. Davis AR, Kroll R, Soltes B, Zhang N, Grubb GS, Constantine GD. Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertil Steril. 2008;89:1059–1063
  13. Greco T, Graham CA, Bancroft J, Tanner A, Doll HA. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception. 2007;76:8–17
  14. Coenen CM, Thomas CM, Borm GF, Hollanders JM, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996;53:171–176
  15. Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception. 1995;51:341–346
  16. Palatsi R, Reinila M, Kivinen S. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne. Acta Derm Venereol. 1986;66:225–230

☆ Clinical trial no. NCT00254189.

☆☆ This study was supported by Wyeth Research.

PII: S0010-7824(09)00086-9

doi: 10.1016/j.contraception.2009.03.006

Contraception
Volume 80, Issue 3 , Pages 245-253 , September 2009

Article Tools

* Image Usage & Resolution